Eli Mordechai, Ph.D.
Chief Executive Officer
Eli Mordechai, Ph.D., is the Founder of the privately-held Genesis Biotechnology Group headquartered in Hamilton, New Jersey. As the Chief Executive Officer, Dr. Mordechai’s forward-thinking leadership inspires and empowers the ongoing discovery and development of innovative scientific products and services that fulfill important clinical needs to enhance the quality of life of patients in the United States and around the world. With visions of executing GBG’s mission of delivering inventive products and services while growing steadily and competitively in the biotechnology marketplace, Dr. Mordechai continues to expand GBG with vertically-integrated business initiatives in mind. Dr. Mordechai’s successes in tactically implementing vertical integration are evidenced by GBG’s collection of operational platforms in laboratory sciences, clinical research, drug discovery, and manufacturing and the comprehensive services, efficiencies, and creativity these collaborative processes yield.
Dr. Mordechai oversees GBG’s day-to-day operations and meets with his senior executive teams on a regular basis to ensure that all the companies of GBG maintain the highest standards of corporate excellence, accountability and transparency. Dr. Mordechai investigates and monitors trends and forecasts in the biotechnology and healthcare industries to manage risk and optimally navigate business development for each of GBG’s enterprises. His focus for GBG’s market expansion involves driving core organic growth, initiating new lines of business, and being an active participant in the merger and acquisition arena. Building executive management teams comprised of industry-leading experts to carry out GBG’s missions and promote its corporate culture of opportunity, honesty, and unsurpassed values and professional practices is another of Dr. Mordechai’s priorities as Chief Officer.
Dr. Mordechai received his Bachelors of Science degree in Biochemistry from Rider University in Lawrenceville, New Jersey, and upon graduation he was distinguished with ‘The Biochemistry Departmental Award’. He went on to earn his Ph.D. in Biochemistry from the Department of Biochemistry at Temple University School of Medicine in Philadelphia. At Temple University, Dr. Mordechai was the recipient of ‘The Florence Gloria Freeman Cancer Research Award’. He completed his post-doctoral studies at the Department of Neurobiology at the Barrow Neurological Institute St. Joseph’s Hospital in Phoenix, Arizona. Following the completion of his post-doctoral studies, he served as the Director of Research and Development at the Immunosciences Laboratory in Beverly Hills, California.
Dr. Mordechai scientific research is documented in over 100 peer-reviewed publications and abstracts. He has presented at a vast array scientific meetings and industry conferences, and he has authored over 25 patents. Dr. Mordechai is an Associate Professor at Rowan University Graduate School of Biomedical Sciences, and he also serves as an active member on many academic and scientific boards such as, Rider University Science Advisory Board, Board of Trustee of Rider University, Chemistry/Biochemistry Advisory Board at Burlington County Community College, Dean Development Council at Rowan University (formally UMDNJ), the Scientific Advisory Board of the Hepatitis B Foundation, and the Pennsylvania Biotechnology Center.
As an accomplished scientist, business executive, and leading community figure, Eli Mordechai, Ph.D.’s body of work and stellar reputation epitomize American ingenuity and have earned him several academic, industrial and community awards, including the Ernest and Young ‘Entrepreneur of the Year’ award. He was voted ‘Most 50 Interesting People in Mercer County’, and he received the esteemed Dean Council Award from the University of Medicine and Dentistry in New Jersey. Dr. Mordechai holds a certificate as a Medical Director from the Wadsworth Center New York State Department of Health and from the American Association of Bioanalysts (AAB). His current professional memberships include the American Society of Microbiology, Association for Molecular Pathology, International Society for Infectious Diseases, and the American Association for the Advancement of Medicine.
Martin E. Adelson, Ph.D.
Chief Operating Officer
Corporate Department and Research Department
Dr. Adelson joined the GBG team in 2002. As the Chief Operating Officer, Dr. Adelson leads clinical, development, and discovery research operations in Medical Diagnostic Laboratories, L.L.C. (MDL), Venenum Biodesign, LLC, and Invivotek LLC, with his main focus concentrating on scaling and expanding the existing business infrastructure through both organic growth and corporate acquisition. In addition, Dr. Adelson implements various innovations and re-engineering initiatives, as well as leverages customized technology solutions, to re-calibrate and enhance MDL’s work flow while reducing overall business costs.
Prior to his appointment to Chief Operating Officer in 2013, Dr. Adelson held positions within MDL as Director of Research & Development before becoming Vice President of MDL in 2007.
Dr. Adelson received his BS in Biology from The College of New Jersey (formerly Trenton State College) in Ewing, NJ. He earned his Ph.D. in Molecular Biology & Genetics from the Department of Molecular Biology and Genetics/Fels Institute for Molecular Biology and Cancer at Temple University School of Medicine in Philadelphia, PA. He completed his postdoctoral studies in the Department of Microbiology and Molecular Genetics at the University of Medicine and Dentistry of New Jersey. Dr. Adleson was the proud recipient of a competitive Postdoctoral Research Fellowship from the National Institutes of Health, National Lung, and Blood Institute.
Dr. Adelson has presented more than 15 presentations for scientific meetings and conferences, clients, and special events. He is the author of 60 publications and 82 abstracts including:
- Adelson ME, Feola M, Trama JP, Tilton RC, and Mordechai E. (2005). Simultaneous detection of herpes simplex virus types 1 and 2 by real-time PCR and Pyrosequencing. Journal of Clinical Virology, 33(1): 15-34. ’s
Dr. Adelson is an Associate Professor at Rowan University Graduate School of Biomedical Sciences as well as a present Member of the Thomas Jefferson University Biotechnology Program Advisory Committee. He has served on the editorial boards of Diagnostic Microbiology and Infectious Disease and Journal of Clinical Microbiology. He has also served as a guest reviewer for the Journal of Clinical Microbiology, Infection & Immunity, Journal of Applied and Experimental Microbiology, Clinical and Diagnostic Microbiology, Journal of Dermatological Science, Diagnostic Microbiology and Infectious Disease, and Clinical and Vaccine Immunology. He serves as a Scientific Advisory Board member of JBS Science, Inc. at the PA Biotechnology Center and is a founding member of the New Jersey and Pennsylvania BioTech and Life Sciences Leadership Council. Dr. Adelson also holds a certificate as a Medical Director from the Wadsworth Center New York State Department of Health. His current professional memberships include the American Society of Microbiology, International Organization for Mycoplasmology, and Association for Molecular Pathology.
Ben Bandaru, Ph.D., MBA
Director of Mergers & Acquisitions
Mergers & Acquisitions Division
Ben joined the GBG team in 2015. As the Director of Mergers and Acquisitions, he provides leadership for strategy development initiatives by working closely with the CEO and strategic business units to drive all acquisitive growth initiatives for GBG and member companies from initiating to closing and on-boarding the transaction. Through collaboration with private equity and investment banks, Ben develops and structures deals, organizes and manages the buy-side, sell-side, intellectual property out-licensing, and joint venture projects to originate new businesses and develop existing relationships.
Prior to GBG, Ben was the Vice President of US Operations, Strategic Programs, and Business Development at iMEDGlobal Corporation. Additionally, Ben held a number of positions in Pfizer Inc., where he served in and led teams in Healthcare Informatics, Acquisition Collaboration and Divestitures, Global R&D, and Global Manufacturing before becoming the Product Development Lead in the Integrated Health Business Unit. During his time with Pfizer, he was the proud recipient of the Pfizer Innovation Award.
Ben received his MBA with a concentration in Strategy from Rensselaer Polytechnic Institute. He earned his Ph.D. in Biochemistry from Wayne State University. Ben also holds a certificate as a Project Management Professional (PMP) from the Project Management Institute.
Ben’s list of publications includes:
- Bandaru, B., Jaishree, G., and and Bhagwat, A. S., 1996, Overproduction of DNA Cytosine Methyltransferases causes Methylation and C to T Mutations at Non-canonical sites, Journal of Biological Chemistry, Vol. 271, No. 13, Issue of March 29, pp. 7851–7859, 1996.
- Bandaru, B., Wyszynski, M., and Bhagwat, A. S., 1995, HpaII methyltransferase is mutagenic in Escherichia coli, Journal of Bacteriology, Vol. 177, No. 10, Issue of May 1995, p. 2950–2952,1995.
- Bandaru, B., 2006, Making team perform at their peak potential, SNEC-PMI, Nov 2006, p.05.
Ben’s hobbies include reading, watching movies, playing tennis and Sudoku.
Chief Financial Officer
Joe joined the GBG team in 2007 as the Accounting Manager. As the Chief Financial Officer since 2011, he is responsible for the accounting and finance functions of all GBG member companies. Joe manages the Accounting Department staff as well as day-to-day operations regarding all cash balances and the maintenance of our internal financial software. He is responsible for establishing and maintaining all banking relationships including financial reporting to banks and third party investors. He provides leadership and strategy development for financial and tax initiatives and is a vital member of the Merger and Acquisition team.
Prior to joining GBG, Joe brought with him twenty years of experience in the financial side of the manufacturing, retail, and distribution industries. Joe previously held positions as Controller of Omnitester Corp as well as Assistant Controller and Credit Manager for The Camera Shop, Inc.
Joe received his BA in Accounting from St. Joseph’s University in Philadelphia, PA.
Joe’s hobbies include spending time with children and grandchildren and spending time at the beach and traveling.
Chief Legal Officer
Susan joined the GBG team in 2011. As the Chief Legal Officer, Susan provides advice and leadership to the GBG family of companies to enhance its position in the fields of clinical diagnostics, drug discovery, product development, manufacturing, and distribution. In addition, Susan structures the transactions for mergers and acquisitions to assist GBG with its strategic growth initiatives in addition to managing a staff of attorneys and outside counsel to address challenges and litigation in the areas of corporate, regulatory, compliance, healthcare, intellectual property, contracts, and employment law.
Prior to her appointment to Chief Legal Officer in 2017, Susan held positions within GBG as Associate Regulatory Counsel 2011-2015, Associate General Counsel 2015-2016, and Deputy General Counsel 2016-2017.
Susan brought twenty five years of Legal experience to the GBG Team through her previous position State of New Jersey Officer of the Attorney General where she served as the Deputy Attorney General.
Susan received her BA & BS in Arts and Science from Pennsylvania State University in State College, PA. She earned her Juris Doctor from Widener University School of Law in Wilmington, DE.
Susan was proud recipient of many awards during her time in the Office of the Attorney General Awards including Excellence in Management 2009, Excellence in Investigations 2009, and Excellence in Trial Litigation 2008. Susan was also awarded with a 2014 Galaxy Award at GBG.
During her free time, Susan enjoys running, cycling, swimming, and movies. She is a Share the Music volunteer and Therapy Dog International volunteer.
Stephanie S. Thompson, MT (ASCP)
Director of Marketing
Stephanie joined the GBG team in 1999. As the Director of Marketing, she provides leadership for the Marketing Department members including the graphic design team. She is responsible for developing, implementing, and maintaining the marketing efforts and supportive collateral for new and existing product lines and services for all GBG Member companies across all lines of business. Stephanie was directly involved in the implementation and supervision of modified processes in the sales and client daily and standing supply order process which streamlined work flow while reducing overall associated business costs.
Stephanie joined Medical Diagnostic Laboratories, L.L.C. (MDL) as a Laboratory Technician in 1999 and has since held various management positions of increasing responsibility. She developed the Quality Control Department for which she became the Quality Control Manager in 2000. As the division continued to grow in both scope and size, in 2004 Stephanie became the Director of Quality Assurance & Quality Control. In 2007, she transitioned into the role of Director of Marketing. Stephanie held a dual Directorship for ten years where she also served as the Director of Administration from 2005 – 2015.
Prior to GBG, Stephanie held a position as a Professional Blood Bank Technologist in the Department of Laboratory Medicine and Transfusion Services at the University of Pennsylvania Hospital in Philadelphia, Pennsylvania.
Stephanie received a BS in Medical Technology from the University of Delaware in Newark, De. She is a board certified Medical Technologist with the American Society of Clinical Pathologists (ASCP).
Stephanie’s hobbies include reading, cooking, and raising a family of three daughters with her husband in South Jersey.
Vice President of Laboratory Operations
Medical Diagnostic Laboratories, L.L.C.
Pete joined the GBG team in 2000. As the Director of Laboratory Operations, he is responsible for the overall operation and administration of a College of American Pathologists (CAP) accredited laboratory including Molecular, Microbiology, Serology, and Pathology Divisions. He ensures the development of Standard Operating Procedures (SOP) and Quality Control/Quality Assurance programs. He is responsible for recruitment and employment needs of all laboratory personnel, selection and maintenance of equipment, safety aspects, QA/QC, and proficiency testing. He takes the lead on all regulatory inspections including CAP, Clinical Laboratory Improvement Act (CLIA), NJ Department of Health, NY Department of Health, and Occupational Safety and Health (OSHA) inspections. Pete serves as Quality Manager for all FDA-related projects as well as a CAP inspector for outside laboratories.
Pete joined MDL as a Laboratory Technician in 2000 and has since held various positions of increasing responsibility including Second Shift Coordinator, Third Shift Coordinator, and Laboratory Manager. In 2005 Pete was promoted to his current position of Director of Clinical Laboratory Operations.
Pete received his BS in Biology from Rutgers University in New Brunswick, NJ.
Director of Laboratory Operations
Medical Diagnostic Laboratories, L.L.C.
Kelly joined the GBG team in 2004. As the Director of Quality Control, Kelly is responsible for overseeing and managing all aspects of clinical laboratory testing for accuracy including the receipt of the test requisition and specimen, accessioning, data entry, testing, and result reporting.
Kelly began her career with MDL as a Laboratory Technician in 2004. In 2005 she became a Clinical Validation Technician and transitioned into the role of Clinical Implementation/Validation Coordinator in 2007. In 2010 Kelly was promoted to Assistant Director of the QA & QC Department. She held this position until 2012 when she became Director of Quality Control.
Kelly received her BS in Biology from Shippensburg University in Shippensburg, PA.
Valerie Tharnish, MT (ASCP)
Vice President of Sales
Medical Diagnostic Laboratories, L.L.C.
Valerie joined the GBG team in 2002. As the Vice President of Sales, she is responsible for the national sales team and increasing revenue quarter-over-quarter by sales directives, incentive plans, and strategic planning.
Valerie joined Medical Diagnostic Laboratories, L.L.C. (MDL) in 2002 as a Senior Sales Executive. In 2004 she was promoted to Regional Sales Manager, a position she held until becoming the National Director of Sales in 2011. In 2013, Valerie assumed her current of Vice President of Sales.
Before joining GBG, Valerie held a position in healthcare recruitment for four years with CJ Ventures as the Vice President of Sales. She was also a Sales Executive with Quest Diagnostics for nine years.
Valerie received her BS in Biology from New College in Sarasota, Fl and her certificate in Medical Technology from the Sarasota Technical Institute. She is a board certified Medical Technologist with the American Society of Clinical Pathologists (ASCP).
John S. Mudgett, Ph.D.
Vice President Drug Discovery Services
Genesis Biotechnology Group
Dr. Mudgett joined the GBG team in 2017. As the Vice President of Drug Discovery Services, he is responsible for leading the integration of all drug discovery services groups and functions. John brings an enthusiastic vision and decades of internal and external pharmaceutical experience to create and grow a holistic customer facing Services Company.
Prior to GBG, John was the owner of JsM BioScience, LLC, where he provided science and business development consultation services to Biotech, CRO, and Scientific Conference business. John was also External Lead – Pharmacology, at Merck Research Laboratories, a position with increasing responsibilities he held for 12 years. At Merck, he was a founding member of the GEM department, tasked with taking an entrepreneurial approach to partnering with internal research to create an inception-to-impact return on investment with external providers in the US and global arenas.
Dr. Mudgett holds a Doctorate and Masters degrees from The Pennsylvania State University and a B.S. with high distinction from The University of Maine. He has completed postdoctoral training at Los Alamos National Laboratory, where he was awarded the Alexander Hollaender Postdoctoral Fellowship Award. In addition, he is a Six Sigma certified greenbelt.
John serves as a Scientific Advisor to the Panel of Scientific Consultants for the International Mouse Phenotyping Consortium (IMPC), funded by the NIH Common Fund. He also serves as a member of the Scientific Advisory Board for PHENOMIN, the French National Infrastructure for Mouse Phenogenomics.
Sherute, Genesis Investment Properties, LLC.
Elka joined the GBG team in 1999. As the President of Sherute, LLC., she is directly involved in Sherute’s day-to-day operations. She is responsible for the strategic planning, designing, and implementation of decor and furnishings of all GBG member companies and properties encompassing an estimated 400,000 square feet of administrative offices, conference rooms, clinical laboratories, hospitality and residential spaces. She provides leadership to all teams within Sherute including construction, facilities maintenance and environmental services, as well as landscape design and snow removal. Elka provides guidance to the GBG web development team regarding the design aspects of all GBG company websites.
Elka began her career with Medical Diagnostic Laboratories, L.L.C. (MDL) in the clinical Laboratory in 1999 orchestrating and supervising laboratory accessioning. In 2007 she founded Sherute, LLC., and has since served as President. Elka is also currently a principal of Genesis Investment Properties, LLC.
Elka is a graduate of Vizo Technical School in Tel Aviv, Israel. Her extensive international travels and subsequent exposure to various world cultures can be seen in the global influence of her designs.
Elka is the proud mother of three and grandmother to one beautiful little girl. Her hobbies include traveling, a love of plants, and baking for family and friends.
Vice President of Acquisition & Business Development
Genesis Investment Properties
Michael joined the GBG team in 2004. As the Vice President of Acquisitions & Business Development, he directs national acquisitions, dispositions, and leasing programs in support of corporate real estate investment goals. He also oversees the development of commercial and mixed-use properties as well as the property management activities for the Corporate real estate portfolio.
Michael initially joined Medical Diagnostic Laboratories, L.L.C. (MDL) in 2004 as the Operations Manager, a position he held until becoming the Director of Operations one year later. In 2007, he transitioned into the role of Director of Operations for Sherute, LLC., a position he held until 2009 when he was appointed Vice President of Operations. In 2010, Michael assumed his current position with Genesis Investment Properties as the Vice President of Acquisitions & Business Development.
Before joining GBG, Michael held a position with Congoleum Corporation as Manager of Administrative Services.
Michael received his BS in Business Administration from Rider University in Lawrenceville, NJ.
Worldwide Life Sciences
Chris joined the GBG team in 2009. As the President of both WWLS and Bioplast Manufacturing, he oversees the development of the Sales and Manufacturing Division of GBG. As part of this development, he continuously strives to create and realize efficiencies that can help both entities become more competitive in the global life science and injection molding marketplace.
Chris initially joined Medical Diagnostic Laboratories, L.L.C. (MDL) IT Department as an IT Network Administrator in 2003 and has since held various management positions of increasing responsibility. He moved into MDL’s Purchasing Department as the Purchasing Manager in 2004. In 2004 he cofounded WorldWide Life Sciences and held the position of Director of Operations until 2015 when he was appointed President of WWLS. Chris is also a cofounder of Bioplast Manufacturing where he held the position of Director of Operations from 2009 until 2015 when he was appointed President of Bioplast as well.
Chris received his BS in Information Technology from Richard Stockton University of New Jersey (formerly Stockton State College) in Galloway, NJ.
Brian joined the GBG team in July 2000. As the Director of Operations for Bioplast, Brian is responsible for the overall operation and administration of an ISO 9001 certified injection molding manufacturing company, specializing in laboratory plastic ware and disposables. He is responsible for the recruitment and employment needs for the production and maintenance staff, selection of primary and auxiliary equipment, and leading the development and implementation of the QMS for ISO 9001. He is responsible for tooling, equipment and automation fabrication timelines, costs, and delivery schedules.
Brian initially joined MDL as a Laboratory Technician in 2000. In 2002 he became Third Shift Coordinator, a position he held until 2009 when he transitioned into his current role at Bioplast Manufacturing.
Brian received his BA in Biology from Rutgers University in New Brunswick, NJ.
Director of Revenue
Medical Diagnostic Laboratories, L.L.C.
Joe joined the GBG team in 2014. As the Director of Revenue, he is responsible for the overall operations and various teams within the billing department. Joe oversees the billing of Managed Care Organizations, patient’s, and client’s as well as reimbursement and collection activities.
Joe brought 20 years of experience in the Medical Billing industry to the GBG Team. He was the owner of Apex Resource which focused on Medical Billing.
Joe received his BS in Accounting from St. Joseph’s University in Philadelphia, PA.
Kathryn T. Iacono, Ph.D.
Director of Administration
Medical Diagnostic Laboratories, L.L.C.
Dr. Iacono joined the GBG team in 2006. As the Director of Administration, she is responsible for overseeing the Customer Service and Data Entry divisions. She serves as a technical specialist to both physician clients and patients whereby she addresses questions concerning MDL’s testing platforms and methodologies as well as treatment options and interpretation of laboratory results for physicians and other healthcare practitioners.
Dr. Iacono began her career with MDL in the Research & Development Department as the Clinical Development Team Leader. In 2014, Dr. Iacono transitioned into the roles of Technical Sales Specialist and Customer Service Manager within the Administration Department. In 2015, she was promoted to her current position as Director of Administration.
Dr. Iacono received her BS in Biology from Muhlenberg College in Allentown, Pa. She earned her Ph.D. in Molecular Biology & Genetics from the Department of Molecular Biology and Genetics/Fels Institute for Molecular Biology and Cancer at Temple University School of Medicine in Philadelphia, PA. Dr. Iacono completed her post-doctoral fellowship in Neurovirology at the University of Pennsylvania in Philadelphia, PA.
Scott Gygax, Ph.D.
Vice President & Managing Director of Product Development
Genesis Biotechnology Group
Dr. Gygax joined the GBG team in 2004. As the Vice President & Managing Director of Product Development of GBG, he oversees a company-wide multidisciplinary team responsible for identifying market opportunities and leveraging GBG’s strengths to develop, launch, and maintain new product brands. Dr. Gygax directs all collaborative efforts of the team members involved in research and development, manufacturing, marketing, sales, and product distribution. He identifies opportunities for new collaborations which focus on the development and validation of medical diagnostic assays, microbiological testing products and diagnostic devices directed toward FDA CMA & 510(k) approval and ISO13485, ISO9001:2015, and FDA 21 CFR 820 / cGMP product manufacturing.
Dr. Gygax began his career with MDL as a Research Scientist in the Research & Development Department, Molecular and Cellular Biology Division in 2004. In 2007, he became Team Leader of the Medical Microbiology/Antimicrobial Resistance group and then Director of FEMERIS Women’s Health Research Center in 2010. In 2016 he transitioned into his current role as Vice President & Managing Director of Product Development of GBG.
Dr. Gygax received a BS in Molecular Biology and Biochemistry from Gettysburg College in Gettysburg, PA. He earned a Ph.D. in Biomedical Science from the University of Connecticut Health Center in Farmington, CT. Dr. Gygax completed his post-doctoral fellowship in Pediatric Infectious Disease at Yale University School of Medicine in New Haven, CT.
Michael McQueney, Ph.D.
Oncoveda Cancer Research Center
Dr. McQueney joined the GBG team in 2009. As the Managing Director of Oncoveda Cancer Research Center, he oversees all research efforts currently focused on the discovering and optimizing novel small molecules to induce the immune system to attack tumors as a way to treat cancer. Dr. McQueney’s group is taking a two pronged approach by looking for ways to both induce an innate immune response and to inhibit immunosuppressive molecules already in the tumor microenvironment. Oncoveda identifies new immuno-oncology drug targets and develops novel assays to be used in high throughput screening and in medicinal chemistry efforts to optimize screening hits into new drugs.
Dr. McQueney began his career with VENENUM Biodesign as the Assistant Manager of High Throughput Screening. In 2011 he became the Screening and Compound Management Team Leader, a position he held until 2014 when he became the Discovery Biology Senior Team Leader. In 2016, Dr. McQueney transitioned into his current role as the Managing Director of Oncoveda Cancer Research Center.
Dr. McQueney brought 14 years of experience in Drug Development to the GBG Team. He previously held positions at SmithKlineBeecham as an Investigator and at GlaxoSmithKline as a Manager.
Dr. McQueney received his BS in Chemistry from Millersville University of Pennsylvania in Millersville, PA. He earned his Ph.D. in Bioorganic Chemistry at University of Maryland in College Park, MD. Dr. McQueney completed his post-doctoral fellowship in Cancer Research at Fox Chase Cancer Center in Philadelphia, PA.
Brian McGuinness, Ph.D.
Director of Chemistry
Dr. McGuinness joined the GBG team in 2010. As the Director of Chemistry, he oversees a team of medicinal chemists in the optimization of small molecule therapeutic compounds aimed at immuno-oncology targets, metabolic disorders, and infectious disease. He also guides the bioanalytical characterization of lead molecules through pharmacokinetic and Absorption, Distribution, Metabolism and Excretion (ADME) studies. In addition, Dr. McGuinness is responsible for the maintenance and growth of Venenum’s 5.7 million member compound collection for high-throughput screening.
Dr. McGuinness began his career with VENENUM Biodesign as the Medicinal Chemistry Team Leader. In 2014 he was promoted to his current position as Director of Chemistry.
Dr. McGuinness brought 17 years of experience in the Pharmeceutical, Peptide and Medicinal Chemistry industries. He previously held positions with PerSeptive Biosystems as a Senior Scientist, Pharmacopeia as a Senior Principal Scientist, and Ligand Pharmaceuticals as a Senior Research Investigator.
Dr. McGuinness received his BS in Chemistry from St. Joseph’s University in Philadelphia, PA. He earned his M. Phil.; PhD. in Organic Chemistry at Columbia University in New York, NY. Dr. McGuinness completed his National Institutes of Health (NIH) post-doctoral fellowship in Organic Chemistry from the Massachusetts Institute of Technology.
James Beasley, Ph.D.
Director of Biology
Dr. Beasley joined the GBG team in 2011. As Venenum’s Director of Biology, he oversees a team of scientists that support the research efforts in GBG’s pre-clinical drug discovery programs in therapeutic areas such as metabolic disorders, oncology, and infectious disease. Dr. Beasley’s Discovery Biology team specializes in the development, optimization, and execution of assays in the ultra-high-throughput screening (uHTS) of Venenum’s 5.7 million member compound library. The team also develops and performs assays, including several ADME-Tox assays, necessary to profile the small molecule therapeutic compounds produced by medicinal chemistry. Dr. Beasley serves as a member of the GBG Executive Council.
Dr. Beasley began his career with VENENUM Biodesign as the Discovery Biology Team Leader. In 2014 he was promoted to his current position as Director of Discovery Biology.
Dr. Beasley brought 12 years of experience in the Drug Discovery industry. He previously held positions with Ligand Pharmaceuticals as a Senior Research Investigator, Pharmacopeia as a Senior Principal Scientist, and DGI Biotechnology as a Senior Scientist.
Dr. Beasley received his BS in Chemistry from University of Texas at Austin in Austin, TX. He earned his PhD. in Chemistry at University of North Carolina at Chapel Hill in Chapel Hill, NC. Dr. Beasley completed his post-doctoral fellowship at Princeton University in Princeton, NJ.
Joseph Nickels, Ph.D.
Institute of Metabolic Disorders
Dr. Nickels joined the GBG team in 2007. As the Managing Director of the Institute of Metabolic Disorders, he oversees all research efforts currently focused on the discovery and development of novel therapeutics, with a special focus on for the treatment of lipid-dependent fatty liver disease (NAFLD/NASH).
Dr. Nickels began his career with MDL in the Research & Development Department, Division of Pharmacogenomics as a Team Leader. In 2009 he transitioned into the role of Scientific Director of VENENUM Biodesign and then Director of Target Biology in 2010. In 2012, Dr. Nickels became the Managing Director of the Institute of Metabolic Disorders.
Prior to joining GBG, Dr. Nickels was a professor of Molecular Biology at Drexel University College of Medicine in Philadelphia, PA for ten years. He has continued his role in Academia in recent years at UMDNJ-School of Osteopathic Medicine in the Department of Molecular Biology and Rowan University School of Medicine in the Department of Molecular Biology.
Dr. Nickels received his BS in Biochemistry from Rider University in Lawrenceville, NJ. He earned his Ph.D. in Molecular Genetics and Microbiology at Rutgers University in New Brunswick, NJ. Dr. Nickels completed his post-doctoral fellowship in Genetics at Princeton University in Princeton, NJ.
Director of Operations
Medical Diagnostic Laboratories, L.L.C.
Bill joined the GBG team in 2009. As the Director of Operations, he oversees the Logistics, FST, Shipping & Receiving, Warehouse, Fleet and Operations divisions and personnel. Bill is responsible for ensuring the efficient and timely transport of all specimens to the laboratory. He continuously works to develop new processes and procedures to increase efficiencies and drive down ever growing operational costs. He works to improve the business processes for the department through analysis and collaboration with other departments.
Bill joined MDL as the Operations Manager of Sherute, LLC., a position he held until 2011 when he became Assistant Director of Operations. In 2016, Bill transitioned into his current role as Director of Operations of MDL.
Bill brought more than twenty years of experience in Operations and Facilities Management to the GBG team. He proudly served his country in the US Navy as an Operations Specialist 2nd Class Petty Officer with a concentration in Combat Information Center Operations. He previously held positions at California Closet Company as a Foreman with a concentration in cabinetry and at Congoleum Corporation in Administrative Services as a Facilities Manager.
Bill received a Certificate of Completion from the US Navy Nuclear Power “A” School and has been working towards a BA in Business Management from Rider University College of Continuing Studies.
David Hilbert, Ph.D.
Femeris Women’s Health Research Center
Dr. Hilbert joined the GBG team in 2006. As the Managing Director of Femeris Women’s Health Research Center, he oversees all research efforts currently focused on the discovery and development of novel therapeutics and diagnostics in the areas of infectious disease and the human microbiome, with a special focus on women’s health.
Dr. Hilbert began his career with MDL in the Research & Development Department as a Research Scientist. In 2011 he became a Team Leader, a position he held until 2013 when he was promoted to Assistant Director of Femeris. In 2016, Dr. Hilbert transitioned into his current position as Managing Director.
Dr. Hilbert received his BS in Biology from The College of New Jersey in Ewing Township, NJ. He earned his Ph.D. in Microbiology at Temple University in Philadelphia, PA. Dr. Hilbert completed his post-doctoral fellowship in Microbiology at Columbia University in New York, NY.
Director of Quality Assurance
Medical Diagnostic Laboratories, L.L.C.
Kim joined the GBG team in 1998. As the Director of Quality Assurance, Kim is responsible for maintaining federal and state licensing for the Clinical Laboratory as well as all regulatory compliance.
Kim joined MDL as a Laboratory Technician in 1998 and has since held various management positions. She was manager of the Clinical Laboratory until 2007 when she became Director of the Quality Assurance (QA) & Quality Control (QC) Department. She held this position until 2012 when she became Director of Quality Assurance, enabling her to focus on licensing and regulatory compliance issues.
Kim received her BS in Biology from Temple University in Philadelphia, PA.
John R. Vogel, Jr.
Director of Property Management
Genesis Investment Properties
John joined the GBG team in 2009. As the Director of Property Management, he coordinates due diligence for all construction inspections for any potential GIP properties. He has direct oversight of both preventive and corrective service measures for all properties in the GIP property portfolio.
John joined Sherute, LLC., in 2009 as the Director of Construction Services. He held this position until 2014 when he transitioned into his current role with GIP.
John brought 25 years of experience in the construction industry to the GBG Team. He previously held positions at C&T Associates as a Project Manager with a focus on utility and municipal construction, Costanza Builders as the Vice President of Construction Management with a focus in commercial construction, and Vogel Building Partners as President with a focus of commercial construction consulting and coordination.
John received his BS in Construction Management from Spring Garden College in Philadelphia, PA.
Olesia Buiakova, M.D., Ph.D.
Dr. Buiakova joined the GBG team in 2013. As the Chief Scientific Officer of Invivotek oversees a multidisciplinary pre-clinical contract research team of Ph.D., MS, and BS scientists dedicated to evaluating therapeutic approaches in the areas of oncology, immunology, metabolic and infectious diseases. She is responsible for establishing and managing pre-clinical animal research programs for several big Pharma and biotech companies, including in vivo pharmacology programs for sister companies at GBG. Dr. Buiakova identifies opportunities for new collaborations and serves as a member of GBG Executive Council.
Dr. Buiakova began her career with GBG as the Vice President of Biology for Invivotek in 2013. Later that year, she transitioned into her current role as Chief Scientific Officer.
Prior to joining GBG, Dr. Buiakova held multiple positions of increasing responsibility including Director at Taconic CRO Division (formerly Xenogen Biosciences) with a concentration in in vivo pharmacology. She also spent three years at Columbia Genome Center at Columbia University, New York, NY concentrating on animal models of human disease.
Dr. Buiakova earned an MD in Medical Biochemistry at the Russian State Medical University in Moscow, Russia. She earned a Ph.D. in Molecular Biology at the Institute for Molecular Genetics of Russian Academy of Sciences in Moscow, Russia. Dr. Buiakova completed her post-doctoral fellowship in Molecular Neurobiology at Hoffmann-La Roche Institute for Molecular Biology in Nutley NJ.
Steven J. Weber, M.H.S.A., Ph.D.
Dr. Weber joined the GBG team in 2017. As the Managing Director of PharmOptima he oversees a multidisciplinary pre-clinical contract research team of Ph.D., MS, and BS scientists dedicated to evaluating therapeutic approaches in the areas of drug absorption, distribution, metabolism, and excretion (ADME), pharmacokinetics (PK), and pharmacology. He oversees teams responsible for discovery and development bioanalysis, biochemistry, in vitro and cell based assay development, protein cloning and expression, .and the custom development of enzyme-linked immunosorbent assays (ELISA) and electrochemiluminescence multiplex formats. Dr. Weber is responsible for establishing and managing pre-clinical animal research programs for several big Pharma and biotech companies with niche experience in the ocular field. He identifies opportunities for new collaborations and serves as a member of GBG Executive Council.
Prior to joining GBG, Dr. Weber held multiple positions of increasing responsibility including Director at Oread Laboratories, Searle, Pharmacia, and then Pfizer as Senior Director. Dr. Weber was also the founder of Part 58 Consulting. He joined PharmOptima in 2011 as Vice President and Chief Operations Officer (COO). He transitioned into the role of Chief Executive Office (CEO) of PharmOptima in 2015. Dr. Weber is an Assistant Research Professor in the Dept. of Biomedical Sciences within the Western Michigan University School of Medicine.
Dr. Weber received his B.S. in Biology from the University of South Dakota in Vermillion, SD. He also earned his Ph.D. in Physiology & Pharmacology from the University of South Dakota. Dr. Weber completed his post-doctoral training at the University of Arizona’s College of Medicine, Department of Pharmacology in Tucson, AZ. In 2010, Dr. Weber also received a Masters in Health Services Administration from the University of Michigan, School of Public Health in Ann Arbor, MI.
Director of Operations
Pete joined the GBG team in 2006. As the Vice President & Director of Operations, oversees the operations of construction and facility services for Sherute LLC.
Pete initially joined MDL as a Project Manager. In 2007 he transitioned to the position of Project Manager for Sherute, LLC. In 2009 he became Senior Project Manager, a position he held until 2014 when he assumed his current role as Vice President & Director of Operations.
Pete brought 14 years of experience in the construction industry to the GBG Team. He previously held positions at CHR Construction Inc., as Project Manager with a focus on residential construction, DRB Developers and Builders LLC., as Carpentry Foreman and Project Manager with a focus in Residential & Commercial Construction, and Advanced Construction Group LLC., as Carpentry Foreman and Project Manager with a focus of commercial construction.
Pete received his AA in General Studies from Clarks Summit University in South Abington Township, PA. He has also completed additional course work in Project Management Studies at Mercer County Community College in West Windsor Township, NJ.
Boris joined the GBG team in 2017. As the Director of IT he is responsible for the strategic planning, design, implementation, and overall alignment of all technology infrastructure with the organizational goals GBG and its member companies. Boris directs the effective delivery of networks, applications, and disaster recovery and processes. He oversees a team of technology engineers, architects, and developers while working closely with management, external vendors, and advisors. Boris identifies solutions to manage daily business activities more efficiently through technological improvements which increase productivity and reduce costs and downtime.
Prior to joining GBG, Boris brought with him twenty years of experience in the information technology industry. He previously held positions as technical lead senior solution advisor at Anthem BC/BS and team lead of application modernization at Gap Gemini America.
Boris received his BS in Information Technology at Kiev National Polytechnic University in Kiev, Ukraine.
Josh joined the GBG team in 2007. As the Director of Quality Control, he is responsible for overseeing and managing all aspects of clinical laboratory testing for accuracy including the receipt of the test requisition and specimen, accessioning, data entry, testing, and result reporting.
Josh began his career with MDL as a Laboratory Technician in 2007. In 2008 he became a Quality Control Technician. Josh transitioned into the role of evening shift QC Coordinator in 2012. In 2016 Josh was promoted to QC Manager, a position he held until 2017 when he transitioned into the role of Director of Quality Control.
Josh received his BS in Life Science with a concentration in Biology from Pennsylvania State University in State College, PA.
Stephen G. Ruby, M.D., M.B.A.
President & Medical Director
Dr. Ruby joined the GBG team in 2017. As the President and Medical Director of 4path, Ltd, he is responsible for leading.
Dr. Ruby brought more than 25+ years of Anatomic and Clinical Pathology experience to the GBG team. He previously founded and independently operated 4path, Ltd for over 10 years. He was also the founder of CAS reference laboratory the Cell Control Sciences. He served as Chairman and Medical Director at a large community hospital (400+ beds) for more than 10 years.
Dr. Ruby holds a B.S. in Biology from Wayne State University in Detroit, Michigan, an M.B.A. and B.S. from Benedictine University in Lisle, Illinois, and an M.D. from Wayne State University in Detroit, Michigan. He completed his residency in Anatomic and Clinical Pathology, St. John Hospital in Detroit, Michigan and a Fellowship in Surgical Pathology at William Beaumont Hospital in Royal Oak Michigan.
Dr. Ruby has served as President of the Illinois Society of Pathology, Chairman on a Practice Management Committee for the College of American Pathologists, Section Editor in Quality Assurance for the Archives of Pathology and Laboratory Medicine and President of the Chicago Pathology Society. He has also authored over 35 peer reviewed journal articles.
Jon C. Sniffen, MDxt (AAB)
Director of Laboratory Operations
Jon joined the GBG team in 2002. As the Director of Laboratory Operations of SunPath-MDL, he is responsible for overseeing and managing all aspects of clinical laboratory operations including recruitment and employment needs of all laboratory personnel. Jon oversees the training and development of all laboratory technical personnel. He monitors compliance with all applicable regulations and provides day-to-day on-site supervision of specimen processing, test performance, and analysis.
Jon began his career with MDL as a Laboratory Technician in 2002 and has since held various positions of increasing responsibility including Assistant Coordinator, Second Shift Coordinator, Laboratory Technology Manager. In 2017 Jon was promoted to his current position of Director of Laboratory Operations for SunPath-MDL.
Jon received his BA in Molecular Biology from Rutgers University in New Brunswick, NJ.